• A case of paroxysmal cold hemoglobinuria complicated by latent syphilis
• A case report of pegcetacoplan use for a pregnant woman with paroxysmal nocturnal hemoglobinuria
• A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria
• A method for selecting P antigen-negative red cell units for patients with paroxysmal cold hemoglobinuria
• A Series of Eight Cases of Pigment Nephropathy: An Obscured Aspect of Acute Kidney Injury
• Abnormal expression of CUX1 influences autophagy activation in paroxysmal nocturnal hemoglobinuria
• Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study
• Acute Necrotizing Pancreatitis Complicated with Paroxysmal Nocturnal Haemoglobinuria: A Case Report
• Advances in research on renal injury in paroxysmal nocturnal
• Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria
• An Interesting Case of Paroxysmal Nocturnal Hemoglobinuria With Renal Involvement
• Analysis and summary of clinical characteristics of 289 patients with paroxysmal nocturnal hemoglobinuria in Zhejiang Province
• Aplastic Anemia With Thrombosis Following the Administration of Immunosuppressant and Thrombopoietin Receptor Agonist (TPO-RA)
• Applications of Flow Cytometry in Diagnosis and Evaluation of Red Blood Cell Disorders
• Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management
• Biomimetic proteolipid vesicles for reverting GPI deficiency in paroxysmal nocturnal hemoglobinuria
• Burden of illness in Japanese patients with paroxysmal nocturnal hemoglobinuria receiving C5 inhibitors
• C5 inhibition in PNH: still effective and safe
• Case report: Immune pressure on hematopoietic stem cells can drastically expand glycosylphosphatidylinositol-deficient clones in paroxysmal nocturnal hemoglobinuria
• CD59 gene: 143 haplotypes of 22,718 nucleotides length by computational phasing in 113 individuals from different ethnicities
• Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region
• Classic paroxysmal nocturnal haemoglobinuria presenting with intestinal malabsorption syndrome, acute abdomen and acute kidney injury
• Coagulation and complement crosstalk: molecular mechanisms of complement-mediated diseases
• Cold-antibody Autoimmune Hemolytic Anemia: its Association with Neoplastic Disease and Impact on Therapy
• Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria
• Comparison of human leukocyte antigen in patients with paroxysmal nocturnal hemoglobinuria of different clone sizes
• Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy
• Consensus recommendations for optimising the diagnosis and treatment of paroxysmal nocturnal haemoglobinuria in Singapore
• Cost-Utility Analysis Comparing Pegcetacoplan to Anti-C5 Monoclonal Antibodies in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
• COVID-19 vaccination prevents a more severe course and treatment with complement inhibitors reduce worsening hemolysis during the Omicron pandemic in patients with PNH: a single-center study
• Crovalimab: First Approval
• Danicopan: First Approval
• Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan
• Diagnostic landscape of first-time cytometric screening for paroxysmal nocturnal hemoglobinuria in Poland in 2013-2022
• Eculizumab for paroxysmal nocturnal hemoglobinuria: Two cases of successful pregnancy outcomes
• Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China
• Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis
• Editorial: Practical recommendations and consensus for the management of immune mediated hematologic diseases
• Efficacy, Safety and Quality of Life of Pegcetacoplan in Japanese Patients With Paroxysmal Nocturnal Hemoglobinuria Treated Within the Phase 3 PEGASUS Trial
• Erratum: Candida krusei pneumonia in graft-versus-host disease after allogeneic hematopoietic stem cell transplant for paroxysmal nocturnal hemoglobinuria: a case report: erratum
• Evaluation of the impact of two C5 genetic variants on C5-eculizumab complex stability at the molecular level
• Expert consensus on clonal screening and monitoring of complement inhibitor therapy in paroxysmal nocturnal hemoglobinuria (2024)
• Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials
• Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria
• Fatigue Item Response among Hemoglobin-Normalized Patients with Paroxysmal Nocturnal Hemoglobinuria: PEGASUS Trial Results at 16 and 48 Weeks
• Health-related quality of life and influencing factors of patients with paroxysmal nocturnal hemoglobinuria in China
• Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
• HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties
• How We Interpret Thrombosis with Thrombocytopenia Syndrome?
• Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry
• Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin 10 g/dL) who had received eculizumab or were naive to complement inhibitors
• Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
• Iptacopan: First Approval
• Kidney R2* Mapping for Noninvasive Evaluation of Iron Overload in Paroxysmal Nocturnal Hemoglobinuria
• Kidney Transplantation After Allogeneic Hematopoietic Cell Transplantation
• Laboratory Evaluation of Immune Hemolytic Anemias
• Life-Threatening Recurrence of Paroxysmal Cold Hemoglobinuria in a Child During Influenza A Infection
• Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
• Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
• Manifestation of Pancytopenia Associated with COVID-19 as Paroxysmal Nocturnal Hemoglobinuria (PNH) and Aplastic Anemia (AA)
• Multisite Thrombosis in a Patient with Paroxysmal Nocturnal Hemoglobinuria
• Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan
• Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria
• Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply
• Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria
• Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043 patient/years analysis
• Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysis
• Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study
• Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
• Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria
• Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
• Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
• Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab
• Pregnancy in acquired bone marrow failure syndromes: Antenatal management and maternal and fetal outcomes
• Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
• Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
• Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)
• RNA therapeutics for disorders of excretory system
• Role of <em>PIGM</em> and <em>PIGX</em> in glycosylphosphatidylinositol biosynthesis and human health (Review)
• Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
• Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
• Several implications for the pathogenesis and treatment of thrombosis in PNH patients according to multiomics analysis
• Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency
• Single-cell sequencing reveals alterations in the differentiation of bone marrow haematopoietic cells in patients with paroxysmal nocturnal haemoglobinuria
• Stable responses to danicopan as add-on to ravulizumab in two patients with paroxysmal nocturnal hemoglobinuria
• Successful haploidentical hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with severe pancytopenia developed after long-term aplastic anemia treatment
• The complement model disease paroxysmal nocturnal hemoglobinuria
• The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms
• The histone demethylase JMJD1C regulates CPS1 expression and promotes the proliferation of paroxysmal nocturnal haemoglobinuria clones through cell metabolic reprogramming
• The immunologic abnormalities in patients with paroxysmal nocturnal hemoglobinuria are associated with disease progression
• The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells
• The metabolic fuel of paroxysmal nocturnal haemoglobinuria
• The role of anticomplement therapy in the management of the kidney allograft
• Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings
• Thrombosis in PNH: largely gone, but not forgotten
• Transformation of aplastic anemia with paroxysmal nocturnal hemoglobinuria clone to childhood B-cell precursor acute lymphoblastic leukemia
• Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis
• Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways
• Unveiling Immunological Signatures and Predictors of Response to Immunosuppressive Therapy in Acquired Aplastic Anaemia"
• What is the role of complement in bystander hemolysis? Old concept, new insights